{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-23-000046","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.083901+00:00","generated_at":"2026-06-08T14:31:02.663137+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Travere Q3 net income $150.7M from bile acid sale; FILSPARI sales $8M, 430 new starts","bullets":["Net income $150.7M ($1.97/share) includes gain from bile acid portfolio sale; prior year loss $69.7M.","FILSPARI net sales $8.0M in Q3, 430 new patient start forms (990 total since Feb 2023 launch).","R&D expense $60.6M, SG&A $67.8M; cash, equivalents & marketable securities $634.6M.","Regulatory: on track for sNDA for FILSPARI in IgAN (full approval) & FSGS in Q4; EU CHMP opinion year-end.","Completed sale of bile acid products to Mirum for up to $445M; pegtibatinase pivotal study to start by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-23-000046","json":"https://secwatch.observer/filing/0001438533-23-000046.json","markdown":"https://secwatch.observer/filing/0001438533-23-000046.md","text":"https://secwatch.observer/filing/0001438533-23-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000046/0001438533-23-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000046/tvtx-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:31:02.663137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1010ebc21444619588b339c3d04c4aef96c8cd94","claim":"Travere Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, Travere Therapeutics, Inc. (the “Company”) issued a press release announcing, among other things, its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000046/0001438533-23-000046-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}